Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIONASDAQ:INDVNASDAQ:LCAPNASDAQ:LFST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$33.65+2.9%$31.15$23.42▼$62.58$1.89B0.73650,533 shs274,744 shsINDVIndivior$13.69-0.3%$12.05$7.33▼$16.50$1.89B0.661.12 million shs720,729 shsLCAPLionheart Acquisition Co. II$26.61+0.8%$10.38$8.94▼$11.70$491.06M0.08102,067 shs2,776 shsLFSTLifeStance Health Group$5.08+2.6%$5.82$4.71▼$8.61$1.92B1.221.64 million shs1.99 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+2.87%-5.21%+11.42%+11.13%-22.39%INDVIndivior-0.29%-1.51%+15.82%+43.20%-16.98%LCAPLionheart Acquisition Co. II-0.29%+1.34%+4.01%+5.68%+5,242.02%LFSTLifeStance Health Group+2.63%+3.04%-16.17%-24.18%+5.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals4.2064 of 5 stars3.41.00.04.23.20.81.9INDVIndivior2.3563 of 5 stars1.65.00.00.02.51.71.9LCAPLionheart Acquisition Co. IIN/AN/AN/AN/AN/AN/AN/AN/ALFSTLifeStance Health Group2.6326 of 5 stars3.42.00.00.02.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.71Moderate Buy$58.6074.15% UpsideINDVIndivior 3.25Buy$15.009.57% UpsideLCAPLionheart Acquisition Co. II 0.00N/AN/AN/ALFSTLifeStance Health Group 2.83Moderate Buy$8.5067.32% UpsideCurrent Analyst Ratings BreakdownLatest LCAP, AGIO, LFST, and INDV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025LFSTLifeStance Health GroupUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$8.505/2/2025AGIOAgios PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$74.00 ➝ $71.004/8/2025LFSTLifeStance Health GroupKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$9.004/7/2025LFSTLifeStance Health GroupKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/3/2025LFSTLifeStance Health GroupCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$36.50M53.40N/AN/A$27.02 per share1.25INDVIndivior$1.19BN/A$1.82 per share7.54($2.52) per shareN/ALCAPLionheart Acquisition Co. IIN/AN/A$1.29 per share20.64($2.85) per shareN/ALFSTLifeStance Health Group$1.25B1.58$0.04 per share124.83$3.78 per share1.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.242.99N/AN/A1,798.26%-2.75%-2.52%7/30/2025 (Estimated)INDVIndivior$2M-$0.31N/A8.01N/A-4.02%-97.29%15.74%7/24/2025 (Estimated)LCAPLionheart Acquisition Co. II$3.21MN/A0.00∞N/AN/A-44.30%1.39%N/ALFSTLifeStance Health Group-$57.44M-$0.10N/AN/AN/A-2.78%-2.47%-1.69%8/14/2025 (Estimated)Latest LCAP, AGIO, LFST, and INDV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/24/2025Q2 2025INDVIndivior$0.25N/AN/AN/AN/AN/A5/1/2025Q1 2025AGIOAgios Pharmaceuticals-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 million4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/ALCAPLionheart Acquisition Co. IIN/AN/AN/AN/AN/ALFSTLifeStance Health GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A18.5017.93INDVIndiviorN/A0.880.72LCAPLionheart Acquisition Co. IIN/A0.050.05LFSTLifeStance Health Group0.191.471.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AINDVIndivior60.33%LCAPLionheart Acquisition Co. IIN/ALFSTLifeStance Health Group85.50%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.30%INDVIndiviorN/ALCAPLionheart Acquisition Co. II19.40%LFSTLifeStance Health Group3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39057.92 million55.43 millionOptionableINDVIndivior1,051N/AN/ANot OptionableLCAPLionheart Acquisition Co. II318.45 million14.87 millionNot OptionableLFSTLifeStance Health Group10,218388.88 million376.43 millionOptionableLCAP, AGIO, LFST, and INDV HeadlinesRecent News About These CompaniesBrokerages Set LifeStance Health Group, Inc. (NASDAQ:LFST) Price Target at $8.50June 20, 2025 | americanbankingnews.comLifeStance Health Group, Inc. (NASDAQ:LFST) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 17, 2025 | marketbeat.comAfter Plunging 9.9% in 4 Weeks, Here's Why the Trend Might Reverse for LifeStance Health (LFST)June 16, 2025 | zacks.comRSI Alert: LifeStance Health Group (LFST) Now OversoldJune 15, 2025 | nasdaq.comSmithbridge Asset Management Inc. DE Invests $563,000 in LifeStance Health Group, Inc. (NASDAQ:LFST)June 13, 2025 | marketbeat.comLFST Q1 Earnings Call: Outpatient Behavioral Health Sees Stable Growth, Margin Improvement, and Shifts in Clinician IncentivesJune 11, 2025 | msn.comTwo Sigma Investments LP Purchases New Shares in LifeStance Health Group, Inc. (NASDAQ:LFST)June 11, 2025 | marketbeat.comLifeStance Health Group, Inc. (NASDAQ:LFST) Insider Ujjwal Ramtekkar Sells 16,000 SharesJune 9, 2025 | marketbeat.comWall Street Analysts Think LifeStance Health (LFST) Could Surge 45.04%: Read This Before Placing a BetJune 5, 2025 | zacks.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in LifeStance Health Group, Inc. (NASDAQ:LFST)June 4, 2025 | marketbeat.comNuveen Asset Management LLC Has $3.11 Million Stock Holdings in LifeStance Health Group, Inc. (NASDAQ:LFST)June 2, 2025 | marketbeat.comWellington Management Group LLP Grows Stock Holdings in LifeStance Health Group, Inc. (NASDAQ:LFST)June 1, 2025 | marketbeat.comLifeStance Health Group, Inc. (NASDAQ:LFST) Position Increased by Bank of America Corp DEJune 1, 2025 | marketbeat.comLifeStance to Present at the 46th Annual Goldman Sachs Healthcare ConferenceMay 28, 2025 | globenewswire.comLifeStance Health Group (NASDAQ:LFST) Shares Gap Up - Time to Buy?May 28, 2025 | marketbeat.comLifeStance Health Group (NASDAQ:LFST) Rating Increased to Buy at UBS GroupMay 28, 2025 | marketbeat.com61,247 Shares in LifeStance Health Group, Inc. (NASDAQ:LFST) Acquired by D. E. Shaw & Co. Inc.May 28, 2025 | marketbeat.comDeutsche Bank AG Raises Stake in LifeStance Health Group, Inc. (NASDAQ:LFST)May 28, 2025 | marketbeat.comUBS Upgrades LifeStance Health Group (LFST)May 27, 2025 | msn.comSouthwest bag fees, LifeStance upgrade, AutoZone earningsMay 27, 2025 | finance.yahoo.comQ1 Earnings Highlights: LifeStance Health Group (NASDAQ:LFST) Vs The Rest Of The Outpatient & Specialty Care StocksMay 26, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLCAP, AGIO, LFST, and INDV Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$33.65 +0.94 (+2.87%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$34.92 +1.27 (+3.77%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Indivior NASDAQ:INDV$13.69 -0.04 (-0.29%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$13.54 -0.15 (-1.13%) As of 04:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Lionheart Acquisition Co. II NASDAQ:LCAPLionheart Acquisition Corporation II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in PropTech sector. The company was incorporated in 2019 and is based in Miami, Florida.LifeStance Health Group NASDAQ:LFST$5.08 +0.13 (+2.63%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$5.10 +0.01 (+0.30%) As of 06/26/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
